Neurofibromatosis Sarcoma Relapse / Refractory
Neurofibromatosis Sarcoma Relapse / Refractory
22-393: A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
- Ages: 12 Months and older
The purpose of this study is to find out whether selinexor is an effective treatment for people who have a relapsed/refractory Wilms tumor, rhabdoid tumor, MPNST, or another solid tumor that makes a higher than normal amount of XPO1 or has genetic changes that increase the activity of XP01. 22-393: ...More
ADP-0044-004: SPEARHEAD-3 Pediatric Study
- Ages: 2 Years to 21 Years
This is a pediatric basket study to investigate the safety and efficacy of afamitresgene autoleucel in HLA-A*02 eligible and MAGE-A4 positive subjects aged 2-21 years of age with advanced cancers. ADP-0044-004: A Phase 1/2 Open Label, Basket Study to Assess the Safety, Tolerability and Anti-Tumor A ...More
VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors
- Ages: 6 Months to 18 Years
This trial is a multi-center, non-randomized, open-label Phase I/II study evaluating the feasibility and efficacy of vincristine, irinotecan, temozolomide, and atezolizumab in children with relapsed/refractory solid tumors In this study, we will test the combination of atezolizumab with chemotherapy ...More
Contact Us
To learn more about available clinical trials related to solid tumors, contact us at cancer@cchmc.org or 513-636-2799.
Related Studies
- Retinoblastoma New Diagnosis
- Retinoblastoma Relapse / Refractory
- Neurofibromatosis Sarcoma New Diagnosis
- Neurofibromatosis NF2
- Neurofibromatosis Plexiform Neurofibroma
- Neurofibromatosis OPG/Low Grade Glioma
- Neurofibromatosis Other
- Melanoma New Diagnosis
- Melanoma Relapse / Refractory
- Germ Cell Tumor New Diagnosis
- Germ Cell Tumor Relapse / Refractory
- All Other Solid Tumors
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2025 Cincinnati Children's Hospital Medical Center. All rights reserved.
